Watch the on-demand presentation from Martyna Solecka, Scientist at Bristol Myers Squibb, and Matthieu Spriet, PhD, Technical Sales Specialist at Inventia Life Science, exploring how 3D PDAC models can be used to study tumor–stroma interactions and therapeutic response.

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most difficult cancers to model, in part because of its dense, complex tumor microenvironment. Conventional in vitro systems often fail to capture the biological impact of tumor–stroma interactions, limiting their ability to support reliable drug response studies.

In this Technology Networks webinar, Martyna Solecka presents work from Bristol Myers Squibb developing a 3D PDAC model that incorporates extracellular matrix components and cancer-associated fibroblasts to better reflect tumor microenvironment structure and cellular interactions.

The session explores how this model was created, characterized, and applied to support phenotypic assessment of therapeutic assets and standard-of-care drugs. Matthieu Spriet also shares how scalable 3D bioprinting workflows using the RASTRUM platform can support consistent tumor microenvironment model generation for drug discovery applications.

What you'll learn:

• Why conventional in vitro approaches can fall short in representing the PDAC tumor microenvironment
• How a 3D PDAC model incorporating extracellular matrix components and cancer-associated fibroblasts was developed
• How tumor–stroma interactions can influence therapeutic response
• How the model supports comparative phenotypic assessment of therapeutic assets and standard-of-care drugs
• How scalable 3D bioprinting workflows can support reproducible tumor microenvironment model generation

Complete the form below to watch the on-demand presentation.